| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 17, 2004
Accepted on October 8, 2004
From INSERM U541 (T.G.E., M.C., M.D., B.I.L., J.-S.S.), Hôpital Lariboisière, IFR Circulation-Lariboisière, Université Paris, France; and Collège de France (R.T.), Paris, France.
* To whom correspondence should be addressed. E-mail: Jean-Sebastien.Silvestre{at}larib.inserm.fr.
Objective--We analyzed the beneficial therapeutic effect of angiotensin converting enzyme inhibitor (ACEI) on both retinal and hind limb neovascularization in diabetic mice.
Methods and Results--Diabetic mice (streptozotocin, 40 mg/kg) were treated with or without ACEI (Perindopril, 3 mg/kg per day) or AT1 receptor blocker (Candesartan, 20 mg/kg) for 4 months. Hind limb ischemia was then induced by right femoral artery ligature for 1 additional month. In the ischemic leg, angiographic score, capillary density, and foot perfusion were increased by 2.7, 2.0-fold, and 1.6-fold, respectively, in ACEI-treated diabetic mice compared with untreated diabetic animals (P<0.01). ACEI also raised vascular endothelial growth factor (VEGF) protein level by 1.4-fold in ischemic diabetic leg. This ACEI pro-angiogenic effect was totally blunted in diabetic bradykinin B2 receptor-deficient animals, suggesting that it was mediated by the bradykinin pathway. In the diabetic retina, angiotensinogen and ACE mRNA levels were increased by 2.8-fold and 4.1-fold, respectively (P<0.01 versus nondiabetic mice), highlighting a local activation of renin-angiotensin system. Diabetes also raised VEGF protein level by 1.5-fold (P<0.05 versus nondiabetic mice). Treatments with ACEI and AT1 receptor blocker hampered diabetes-induced VEGF upregulation and retinal neovascularization.
Conclusion--ACE inhibition improved neovascularization in the diabetic ischemic leg through activation of bradykinin signaling, whereas it reduced vessel growth in the diabetic retina through inhibition of overacting Ang II pathway.
This article has been cited by other articles:
![]() |
C. Clapp, S. Thebault, M. C. Jeziorski, and G. Martinez De La Escalera Peptide Hormone Regulation of Angiogenesis Physiol Rev, October 1, 2009; 89(4): 1177 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Silvestre and B. I. Levy Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors Eur. Heart J. Suppl., August 1, 2009; 11(suppl_E): E17 - E21. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Muller, A. Kazakov, P. Jagoda, A. Semenov, M. Bohm, and U. Laufs ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload Cardiovasc Res, July 1, 2009; 83(1): 106 - 114. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Phipps, A. C. Clermont, S. Sinha, T. J. Chilcote, S.-E. Bursell, and E. P. Feener Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability Hypertension, February 1, 2009; 53(2): 175 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. de Resende, S. L. Amaral, C. Moreno, and A. S. Greene Congenic strains reveal the effect of the renin gene on skeletal muscle angiogenesis induced by electrical stimulation Physiol Genomics, October 8, 2008; 33(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sanchez de Miguel, S. Neysari, S. Jakob, M. Petrimpol, N. Butz, A. Banfi, C. E. Zaugg, R. Humar, and E. J. Battegay B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart Cardiovasc Res, October 1, 2008; 80(1): 106 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Spinetti, N. Kraenkel, C. Emanueli, and P. Madeddu Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies Cardiovasc Res, May 1, 2008; 78(2): 265 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Reed, C. Kolz, B. Potter, and P. Rocic The Mechanistic Basis for the Disparate Effects of Angiotensin II on Coronary Collateral Growth Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann and A. Lerman Atherosclerosis in the Back Yard J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2102 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, et al. Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of Bradykinin Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2321 - 2326. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Miller, L. E. Norton, M. P. Murphy, M. C. Dalsing, and J. L. Unthank The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2523 - H2531. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. G Ebrahimian, C. Heymes, D. You, O. Blanc-Brude, B. Mees, L. Waeckel, M. Duriez, J. Vilar, R. P. Brandes, B. I. Levy, et al. NADPH Oxidase-Derived Overproduction of Reactive Oxygen Species Impairs Postischemic Neovascularization in Mice with Type 1 Diabetes Am. J. Pathol., August 1, 2006; 169(2): 719 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Waeckel, J. Bignon, J.-M. Liu, D. Markovits, T. G. Ebrahimian, J. Vilar, B. Mees, O. Blanc-Brude, V. Barateau, S. Le ricousse-Roussanne, et al. Tetrapeptide AcSDKP Induces Postischemic Neovascularization Through Monocyte Chemoattractant Protein-1 Signaling Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 773 - 779. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |